The Emerging Role of Phosphodiesterase 5 Inhibition in Neurological Disorders: The State of the Art
Cells · 17.10.2024 · 13 (20) · 1720
DOI: 10.3390/cells13201720 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 17.10.2024. Verfasst von Clara Crescioli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Movement, Human and Health Sciences, University of Rome Foro Italico, Piazza Lauro de Bosis, 6, 00135 Rome, Italy. Hauptthemen laut MEDLINE: Phosphodiesterase 5 Inhibitors, Nervous System Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Growing evidence suggests that neuroinflammation is not just a consequence of neurodegeneration in pathologies such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease or Amyotrophic lateral sclerosis, but it is rather a determinant factor, which plays a pivotal role in the onset and progression of these disorders. Neuroinflammation can affect cells and processes in the central nervous system (CNS) as well as immune cells, and might precede protein aggregation, which is a hallmark of the neurodegenerative process. Standard treatment methods are far from being able to counteract inflammation and delay neurodegeneration. Remarkably, phosphodiesterase 5 inhibitors (PDE5is), which represent potent vasoactive drugs used as a first-line treatment for erectile dysfunction (ED), display important anti-inflammatory effects through cyclic guanosine monophosphate (cGMP) level stabilization. Since PDE5 hydrolyzes cGMP, several studies positioned PDE5 as a therapeutic target, and more specifically, PDE5is as potential alternative strategies for the treatment of a variety of neurological disorders. Indeed, PDE5is can limit neuroinflammation and enhance synaptic plasticity, with beneficial effects on cognitive function and memory. The aim of this review is to provide an overview of some of the main processes underlying neuroinflammation and neurodegeneration which may be potential targets for PDE5is, focusing on sildenafil, the most extensively studied. Current strategies using PDEis for the treatment of neurodegenerative diseases will be summarized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Movement, Human and Health Sciences, University of Rome Foro Italico, Piazza Lauro de Bosis, 6, 00135 Rome, Italy.
- Laboratory of Molecular and Cellular Neurobiology, Fondazione Santa Lucia IRCCS, Via del Fosso di Fiorano, 64, 00143 Rome, Italy.
ORCID-Profile: Clara Crescioli, Maria Paola Paronetto
Zitieren
APA
Crescioli, C., & Paronetto, M. P. (2024). The Emerging Role of Phosphodiesterase 5 Inhibition in Neurological Disorders: The State of the Art. Cells, 13(20), 1720. https://doi.org/10.3390/cells13201720
Vancouver
Crescioli C, Paronetto MP. The Emerging Role of Phosphodiesterase 5 Inhibition in Neurological Disorders: The State of the Art. Cells. 2024;13(20):1720. doi:10.3390/cells13201720
BibTeX
@article{Crescioli2024,
author = {Crescioli, Clara and Paronetto, Maria Paola},
title = {The Emerging Role of Phosphodiesterase 5 Inhibition in Neurological Disorders: The State of the Art},
journal = {Cells},
year = {2024},
volume = {13},
number = {20},
pages = {1720},
doi = {10.3390/cells13201720}
}
EUVIMED